The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several data on the efficacy of these agents in inducing and maintaining clinical remission have been accumulated over the past two decades: their use avoid the need for steroids therapy, promote mucosal healing, reduce hospitalizations and surgeries and therefore dramatically improve the quality of life of IBD patients. However, primary non-response to these agents or loss of response over time mainly due to immunogenicity or treatment-related side-effects are a frequent concern in IBD patients. Thus, the identification of predicting factors of efficacy is crucial to allow clinicians to efficiently use these therapies, avoiding them when they are ineffective and eventually shifting towards alternative biological therapies with the end goal of optimizing the cost-effectiveness ratio. In this review, we aim to identify the predictive factors of short- and long-term benefits of anti-TNF-α therapy in IBD patients. In particular, multiple patient-, disease- and treatment-related factors have been evaluated.

Lopetuso, L. R., Gerardi, V., Papa, V., Scaldaferri, F., Rapaccini, G. L., Gasbarrini, A., Papa, A., Can we predict the efficacy of anti-TNF-α agents?, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2017; 18 (9): N/A-N/A. [doi:10.3390/ijms18091973] [http://hdl.handle.net/10807/113177]

Can we predict the efficacy of anti-TNF-α agents?

Lopetuso, Loris Riccardo;Gerardi, Viviana;Papa, Valerio;Scaldaferri, Franco;Gasbarrini, Antonio;Papa, Alfredo
2017

Abstract

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several data on the efficacy of these agents in inducing and maintaining clinical remission have been accumulated over the past two decades: their use avoid the need for steroids therapy, promote mucosal healing, reduce hospitalizations and surgeries and therefore dramatically improve the quality of life of IBD patients. However, primary non-response to these agents or loss of response over time mainly due to immunogenicity or treatment-related side-effects are a frequent concern in IBD patients. Thus, the identification of predicting factors of efficacy is crucial to allow clinicians to efficiently use these therapies, avoiding them when they are ineffective and eventually shifting towards alternative biological therapies with the end goal of optimizing the cost-effectiveness ratio. In this review, we aim to identify the predictive factors of short- and long-term benefits of anti-TNF-α therapy in IBD patients. In particular, multiple patient-, disease- and treatment-related factors have been evaluated.
2017
Inglese
Lopetuso, L. R., Gerardi, V., Papa, V., Scaldaferri, F., Rapaccini, G. L., Gasbarrini, A., Papa, A., Can we predict the efficacy of anti-TNF-α agents?, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2017; 18 (9): N/A-N/A. [doi:10.3390/ijms18091973] [http://hdl.handle.net/10807/113177]
File in questo prodotto:
File Dimensione Formato  
113177OA.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 260.05 kB
Formato Unknown
260.05 kB Unknown Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/113177
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 66
social impact